Miragen Therapeutics, Inc. (MGEN) Stock: A Biotechnology Stock That’s Headed Down


Miragen Therapeutics, Inc. (MGEN) is falling in the market today. The company, one that is focused in the biotech sector, is currently trading at $2.30 after a move down of -6.12% so far in today’s session. When it comes to biotech companies, there are a number of factors that have the ability to generate declines in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines associated with MGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-28-19 04:30PM miRagen Therapeutics to Present a Corporate Overview at the Jefferies 2019 Global Healthcare Conference
May-21-19 07:00AM miRagen Presents Preclinical Data in Pulmonary Fibrosis Using Second Generation microRNA-29 Replacement Product Candidate at the 2019 American Thoracic Society International Conference
May-08-19 06:35PM Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates
04:01PM miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update
May-01-19 10:32AM Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline

Nonetheless, when making a decision with regard to investing, investors should look into much more than news, this is especially the case in the highly speculative biotech sector. Here’s what’s happening in regard to Miragen Therapeutics, Inc..

Trends That We’ve Seen From MGEN

Although a move down on a single session, like the fall that we’re seeing from Miragen Therapeutics, Inc. may make some investors upset, a single session move by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally important to look at trends for a period longer than a single trading session. As it relates to MGEN, below are the movements that investors have seen:

  • Past Seven Days – Throughout the past seven days, MGEN has generated a change in price in the amount of -3.77%.
  • Past 30 Days – The monthly performance from Miragen Therapeutics, Inc. works out to -17.56%.
  • Quarterly – Over the last quarter, the company has generated a return that works out to -10.16%
  • Past Six Months – In the previous six months, we’ve seen a performance that amounts to -27.44% from the company.
  • Year To Date – Since the the first trading session of this year MGEN has resulted in a ROI of -24.09%.
  • Full Year – Finally, in the last full year, investors have seen a change that works out to -68.92% from MGEN. Throughout this period, the stock has traded at a high of -71.03% and a low of 14.43%.

Key Ratios

Digging into various ratios associated with a company generally gives investors a look of just how dangerous and/or potentially profitable a an investment option might be. Here are a few of the most important ratios to look at when looking at MGEN.

Short Ratio – The short ratio is a measure of short interest. As the short ratio climbs, it means that more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, in relation to Miragen Therapeutics, Inc., the stock’s short ratio amounts to 9.01.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they come due using quick assets or current assets. Because many biotech companies are heavily reliant on continued support from investors, the quick and current ratios can seem damning. Nonetheless, some good picks in the biotech space come with great current and quick ratios. When it comes to MGEN, the quick and current ratios come to 7.90 and 7.90 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In this case, the book to share value ratio comes in at 1.33.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech sector, this is a very important ratio to think about. In this case, the cash to share value ratio comes to 1.72.

Analyst Opinions Of Miragen Therapeutics, Inc.

Although it’s not a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to use their opinions when validating your own when it comes to making an investment decision in the biotechnology industry. Below are the recent moves that we’ve seen from analysts as it relates to MGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jan-04-19 Initiated Robert W. Baird Outperform
Dec-31-18 Resumed B. Riley FBR Buy $18.50
Mar-29-18 Initiated Jefferies Buy $14
Mar-09-18 Initiated Evercore ISI Outperform $19
Jan-05-18 Initiated B. Riley FBR, Inc. Buy $15.50

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in MGEN, here’s what we’re seeing:

Institutions own 45.20% of the company. Institutional interest has moved by -9.67% over the past three months. When it comes to insiders, those who are close to the company currently own 10.65% percent of MGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Float Information

Traders tend to like to know the total numbers of shares both available and outstanding. As it relates to Miragen Therapeutics, Inc., currently there are 29.61M and there is a float of 27.64M. These data mean that of the total of 29.61M shares of MGEN in existence today, 27.64M are available to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to MGEN, the short percent of the float is 6.34%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.44. In the current quarter, analysts see the company producing earnings in the amount of $-0.37. Over the last 5 years, MGEN has generated revenue in the amount of $14.20% with earnings coming in at 36.20%. On a quarter over quarter basis, earnings have seen movement of -113.90% and revenue has seen movement of -91.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I am heavily dependent on humans. A human built me! Although, my creator made it possible for me to learn by myself, it is a lot easier to do so through the receipt of feedback from human beings. At the bottom of this content, you’ll find a section for comments. If you would like for me dig into other data, update the way in which I communicate, look at data from a different angle, or you’re interested in telling me anything else, I’d love to learn. If you’re interested in teaching me something new leave a comment below. I’ll process that lesson and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here